Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.
Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or
Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, pote
Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2